Zentek Ltd. · TSX-V: ZEN · Guelph, Ontario · August 2026
Three deep-science platforms - potential nuclear-grade graphite, graphene coatings, and aptamer biosciences - on a single client-funded, development-on-demand CRO model that owns the IP and minimises dilution.
Shareholder notice · Nasdaq listing
Nasdaq has issued a delisting determination against Zentek on the US$1.00 minimum bid price requirement — here is what that changes, what it does not, and what, if anything, you need to do.
Regaining compliance required a closing bid of at least US$1.00 for ten consecutive business days within that window. That condition was not met.
No. You own the same number of shares today that you owned yesterday. A listing is where a share trades. It is not what a share is.
Yes. Our shares trade on the TSX Venture Exchange under ZEN, and that listing is unaffected. It is our primary listing.
Nothing. Your broker trades ZEN on the TSX Venture Exchange the same way it always has.
First, you can hold and trade the TSX Venture line through a broker with Canadian market access. Second, once Nasdaq trading is suspended, our shares are expected to be quoted in the United States over the counter. The symbol is expected to be different from ZTEK. If you search ZTEK after that date and find nothing, that is why. We will publish the exact symbol as soon as the exchange provides it.
No. You do not need to move your account, sell, re-register, or fill in a form.
A letter from Nasdaq saying a company no longer meets a listing rule and its shares are subject to removal from the exchange. It is a step in a process, not the end of one.
An independent panel inside Nasdaq that hears a company’s case. A company that receives a determination can request a hearing. We intend to request one.
Not in our situation. There is a specific Nasdaq rule that removes that protection where the company was in a second 180-day compliance period, which is where we were. Requesting a hearing does keep us registered with the U.S. Securities and Exchange Commission and does keep us filing there.
A U.S. market where shares trade through broker-dealers rather than on a stock exchange. Trades are real and prices are real, and the broker-dealers involved are regulated. It is less visible than Nasdaq: some brokerage screens, screening tools and data feeds cover it less well than they cover an exchange listing.
The OTC market has tiers. We have applied for the top one, OTCQX, and we have paid for the application to be reviewed on an expedited basis. Applications take time to process and we cannot control how long. If the approval is not in hand on the first day of quotation, our shares will be quoted on a lower tier until it is, and we will say which one. We will publish the tier and the symbol before the first day, not after.
We expect trading to be live on OTC on September 2, 2026 at the opening bell, and to transition further to OTCQX shortly thereafter.
We are not going to predict that, and you should be careful with anyone who does. Any step we take on the listing is something we have to disclose publicly, and you will read it from us on the day we take it.
Anything of that kind is a disclosure event, and where shareholder approval is required, it would be put to shareholders in a circular ahead of a meeting. We are not going to get ahead of that. If it is proposed, you will receive the full document, in advance, with time to read it and most importantly to vote.
No. The deposit, our ownership of it, the environmental and community work, and the PEA results we announced on August 10 are all unaffected.
No. Our customer buys filtration media. None of the commercial work is conditioned on which exchange our shares trade on.
No. That financing closed on May 27 for gross proceeds of C$18.0 million. Our cash position is reported in our quarterly financial statements, which are filed on SEDAR+ and EDGAR.
It means our share price did not meet a specific Nasdaq threshold. That is a share price fact. It is not a statement about the assets, the technology, the balance sheet or the work. We would rather you judged us on the dated record since December 1, which is published and which you can check.
Email us at info@zentek.com with the broker’s name and what the screen says. We are tracking this, and where a broker or a data provider has it wrong we go and get it fixed.
Our news releases, our filings on SEDAR+ and EDGAR, and this page. If you see something about Zentek anywhere else, check it here first.
Mohammed (Moe) Jiwan · mjiwan2@zentek.com · 437 826 3779
General enquiries: (844) 730-9822 · info@zentek.com
Listing & capital structure
Zentek Ltd. is a reporting issuer in Canada and a foreign private issuer in the United States, filing on Form 6-K. All financial information is reported in Canadian dollars under IFRS.
Share prices are provided for information only, are delayed by at least 15 minutes, and may differ from the official exchange record. They are not a quotation on which any purchase or sale can be made and do not constitute investment advice.
| Common shares outstanding | 126,619,532 |
| Stock options (exercisable) | 5,311,750 |
| Restricted share units (RSUs) | 1,006,000 |
| Warrants outstanding | 22,461,060 |
| Shares issuable upon conversion of convertible debentures (at $2.20) | ~909,091 |
| Fully diluted shares | ~156,307,433 |
The numbers
Our three platforms are structurally independent: different markets, different buyers, different commercial triggers. Any one of them achieving commercial traction is a re-rating event. All three in motion simultaneously is the full thesis.
Investment strategy
We believe three structural conditions have converged simultaneously: geopolitical tailwinds, commercially-ready science, and a proven model.
Export licensing restrictions introduced in 2023 triggered over $1.8B in North American capacity announcements. Emerging pathogen threats have put significant US government biosecurity funding in play. Supply chain sovereignty is now a national security mandate across all Five Eyes nations: written into procurement frameworks, not just policy papers.
Thirty years of aptamer research is now commercially deployable for the first time. Triera has the team and the IP that makes that possible. Graphene coatings are moving from laboratory to industrial scale. Albany graphite has demonstrated bench-scale purity results consistent with published nuclear-grade thresholds, through independent testing. These are not projections: they are published, peer-reviewed, independently verified results.
The client-funded CRO model - industry brings the problem, Zentek develops the solution and owns the IP - has created multi-billion dollar companies in pharma (Charles River, ICON) and specialty materials (NanoXplore, Aptamer Group). Non-dilutive government funding can potentially offset R&D costs. No manufacturing capex required.
Filings & documents
Corporate presentation, quarterly and annual filings, and regulatory reports. All continuous disclosure documents are also available on SEDAR+ and EDGAR.
The current investor deck covering the three platforms, the client-funded CRO model, and the valuation thesis. View it in the browser or download the presentation.
Investor relations
Zentek is actively seeking strategic partners and long-term investors who recognise the convergence of critical minerals supply chain urgency, advanced air quality requirements, and next-generation therapeutic development. If you are exploring any of these areas, we would like to hear from you.
For investor enquiries, meeting requests, and continuous disclosure questions. Toll-free (844) 730-9822.
ir@zentek.comStrategic partnerships · licensing · co-development opportunities. Toll-free (844) 730-9822.
info@zentek.comInteractive tools · explore the data
Three interactive tools built to help investors, analysts, and technical partners understand the Albany deposit, its economics, and the global graphite market context.
An animated walkthrough of the global graphite supply chain - from mine to reactor - and where Albany sits within it. Built for investor conversations and partner briefings.
Adjust cut-off grade, recovery rates, and market pricing to model Albany's economics in real time. Understand the sensitivity of the project to key variables.
A plain-language explainer covering graphite grades, crystalline structure, processing requirements, and why Albany's igneous-hosted, fluid-derived origin matters for downstream applications.
Forward-looking information
This page contains forward-looking information within the meaning of applicable Canadian and United States securities laws, including statements about market opportunities, development timelines, potential revenue, valuation multiples, and funding sources. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those expressed or implied. Zentek Ltd. (TSX-V: ZEN) is a reporting issuer in Canada and a foreign private issuer in the United States, filing financial reports on Form 6-K under IFRS in Canadian dollars.
Nothing on this page constitutes a mineral resource or reserve estimate under NI 43-101, a medical claim, financial advice, or an offer or solicitation to buy or sell securities. Readers are referred to Zentek's continuous disclosure documents on SEDAR+ and EDGAR for complete risk factor disclosure. Full legal disclaimers →